{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:56:00Z","timestamp":1784645760615,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40261-025-01512-0","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:59:48Z","timestamp":1765969188000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sublingual Cyclobenzaprine: First Approval"],"prefix":"10.1007","volume":"46","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"9","key":"1512_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40265-025-02204-x","volume":"85","author":"H Clarke","year":"2025","unstructured":"Clarke H, Peer M, Miles S, et al. Managing pain in fibromyalgia: current and future options. Drugs. 2025;85(9):1081\u201392.","journal-title":"Drugs"},{"issue":"3","key":"1512_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/jcm14030955","volume":"14","author":"T Filipovic","year":"2025","unstructured":"Filipovic T, Filipovic A, Nikolic D, et al. Fibromyalgia: understanding, diagnosis and modern approaches to treatment. J Clin Med. 2025;14(3):955.","journal-title":"J Clin Med"},{"key":"1512_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.666914","author":"Y Maugars","year":"2021","unstructured":"Maugars Y, Berthelot JM, Le Goff B, et al. Fibromyalgia and associated disorders: from pain to chronic suffering, from subjective hypersensitivity to hypersensitivity syndrome. Front Med. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.666914.","journal-title":"Front Med"},{"issue":"9","key":"1512_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ph17091205","volume":"17","author":"A Alfaro-Rodriguez","year":"2024","unstructured":"Alfaro-Rodriguez A, Reyes-Long S, Roldan-Valadez E, et al. Association of the serotonin and kynurenine pathways as possible therapeutic targets to modulate pain in patients with fibromyalgia. Pharmaceuticals (Basel). 2024;17(9):1205.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1512_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12888-025-06708-4","volume":"25","author":"A Rahangdale","year":"2025","unstructured":"Rahangdale A, Ferraro J. Assessing comorbid PTSD, depression, and anxiety in fibromyalgia patients: a retrospective observational study. BMC Psychiatry. 2025;25(1):444.","journal-title":"BMC Psychiatry"},{"key":"1512_CR6","unstructured":"Merck & Co. Inc. FLEXERIL\u00ae (cyclobenzaprine HCl) tablets: US prescribing information. 1977. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/017821s045lbl.pdf. Accessed 17 Nov 2025."},{"key":"1512_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnaf089","author":"S Lederman","year":"2025","unstructured":"Lederman S, Arnold LM, Vaughn B, et al. Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. Pain Med. 2025. https:\/\/doi.org\/10.1093\/pm\/pnaf089.","journal-title":"Pain Med"},{"key":"1512_CR8","unstructured":"Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals granted Fast Track Designation by FDA for Tonmya\u2122 for fibromyalgia [media release]. 25 Jul 2024. http:\/\/www.tonixpharma.com."},{"key":"1512_CR9","unstructured":"Tonix Pharmaceuticals Inc. TONMYA\u2122 (cyclobenzaprine hydrochloride sublingual tablets): US prescribing information. 2025. https:\/\/www.tonixpharma.com\/wp-content\/uploads\/2025\/08\/Tonmya-Prescribing-Information.pdf. Accessed 17 Nov 2025."},{"key":"1512_CR10","unstructured":"Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals announces FDA approval of Tonmya\u2122 (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia [media release]. 15 Aug 2025. https:\/\/ir.tonixpharma.com\/news-events\/press-releases\/detail\/1585\/tonix-pharmaceuticals-announces-fda-approval-of."},{"key":"1512_CR11","unstructured":"Daugherty B. Pharmacokinetic properties of TNX-102 SL, a sublingual formulation of cyclobenzaprine hydrochloride [oral presentation]. In: 11th Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference. 2024."},{"key":"1512_CR12","unstructured":"Data on file, Tonix Pharmaceuticals, 2025."},{"key":"1512_CR13","unstructured":"Daugherty B, Gershell L, Monti NC, et al. Rapid sublingual absorption of cyclobenzaprine (Cbp) with basifying agents: prospect for bedtime treatment of fibromyalgia syndrome (Fm) [abstract no. LB-026 plus poster]. In: 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. 2016."},{"key":"1512_CR14","unstructured":"Sullivan G, Kiu R, Stillwell H, et al. Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl (TNX-102 SL*): comparison to simulations of oral immediate release CBP [poster no. W29]. In: American Society of Clinical Psychopharmacology (ASCP). 2019."},{"key":"1512_CR15","unstructured":"Sullivan G, Meibohm B, Gould E, et al. Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl (TNX-102 SL): comparison to simulations of oral immediate-release CBP [poster no. 45]. In: PAINWeek Conference. 2025."},{"key":"1512_CR16","unstructured":"Daugherty B, Gershell L, Lederman S. Cyclobenzaprine (CBP) and its major metabolite norcyclobenzaprine (nCBP) are potent antagonists of the serotonin receptor 2A, histamine H1 and \u03b1-adrenergic receptors: mechanistic and safety implications for treating fibromyalgia syndrome by improving sleep quality [poster no. 960]. In: American College of Rheumatology (ACR)\/Association of Rheumatology Health Professionals (ARHP) Annual Meeting. 2013."},{"issue":"Suppl 10","key":"1512_CR17","first-page":"2785","volume":"67","author":"S Lederman","year":"2015","unstructured":"Lederman S, Gendreau M, Clauw D, et al. Bedtime, rapidly absorbed sublingual cyclobenzaprine (TNX-102 SL) for the treatment of fibromyalgia: results of a phase 2b randomized, double-blind, placebo-controlled study [abstract no. 2309 plus poster]. Arthritis Rheumatol. 2015;67(Suppl 10):2785\u20136.","journal-title":"Arthritis Rheumatol"},{"key":"1512_CR18","unstructured":"Sullivan G, Gendreau RM, Gendreau J, et al. A phase 3 randomized, double-blind, placebo-controlled trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) for the treatment of fibromyalgia (FM): evidence for a broad spectrum of activity on the FM syndrome [oral presentation]. In: American College of Rheumatology Annual Meeting. 2019."},{"key":"1512_CR19","unstructured":"ClinicalTrials.gov. Repeat of: a study to evaluate efficacy and safety of sublingual TNX-102 SL tablet taken at bedtime in patients with fibromyalgia. 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02829814. Accessed 17 Nov 2025."},{"issue":"11","key":"1512_CR20","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/acr.25142","volume":"75","author":"S Lederman","year":"2023","unstructured":"Lederman S, Arnold LM, Vaughn B, et al. Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2023;75(11):2359\u201368.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1512_CR21","unstructured":"Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals announces outcome of interim analysis of phase 3 RALLY study of TNX-102 SL for the management of fibromyalgia [media release]. 23 Jul 2021. http:\/\/www.tonixpharma.com."},{"key":"1512_CR22","unstructured":"ClinicalTrials.gov. A phase 3 study to evaluate the efficacy and safety of TNX-102 SL in patients with fibromyalgia (RALLY). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04508621. Accessed 17 Nov 2025."},{"key":"1512_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.113974","volume":"301","author":"GM Sullivan","year":"2021","unstructured":"Sullivan GM, Gendreau RM, Gendreau J, et al. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021;301:113974.","journal-title":"Psychiatry Res"},{"issue":"115764","key":"1512_CR24","first-page":"1","volume":"334","author":"ME Parmenter","year":"2024","unstructured":"Parmenter ME, Lederman S, Weathers FW, et al. A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder. Psychiatry Res. 2024;334(115764):1\u20139.","journal-title":"Psychiatry Res"},{"key":"1512_CR25","unstructured":"ClinicalTrials.gov. A phase 3 study to evaluate the efficacy and safety of TNX-102 SL in participants with PTSD (RECOVERY). 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02829814. Accessed 17 Nov 2025."},{"key":"1512_CR26","unstructured":"Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals announces outcome of interim analysis for phase 3 RECOVERY study of Tonmya\u00ae (TNX-102 SL) in PTSD [media release]. 5 Feb 2020. http:\/\/www.tonixpharma.com."},{"key":"1512_CR27","unstructured":"Harris H, Engels J, Vaughn B, et al. Effect of bedtime sublingual cyclobenzaprine (TNX-102 SL) on pain, sleep, fatigue and cognition in fibromyalgia-type long covid: Results of a double-blind randomized proof-of-concept phase 2 study [abstract no. T16 plus poster]. In: American Society of Clinical Psychopharmacology Annual Meeting. 2024."},{"key":"1512_CR28","unstructured":"Hsu D, Jones CW, Germine L, et al. Optimizing acute stress reaction (ASR) interventions with TNX-102 SL* (sublingual cyclobenzaprine HCl) \u2013 the OASIS trial: sustaining civilian performance post-trauma by reduction of ASR and prevention of ASD\/PTSD [poster]. In: American Society of Clinical Psychopharmacology Annual Meeting. 2024."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01512-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01512-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01512-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:37:24Z","timestamp":1768833444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01512-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1512"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01512-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}